Qing Song Health Co.,Ltd. (TPE:6931)
Taiwan · Delayed Price · Currency is TWD 51.10
-3.40 (-6.24%)
At close: Mar 19, 2026
Qing Song Health Revenue
In the year 2025, Qing Song Health had annual revenue of 1.12B TWD with 14.16% growth. Qing Song Health had revenue of 296.77M in the quarter ending December 31, 2025, with 15.74% growth.
Revenue
1.12B
Revenue Growth
+14.16%
P/S Ratio
3.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12B | 139.14M | 14.16% |
| Dec 31, 2024 | 982.56M | 113.90M | 13.11% |
| Dec 31, 2023 | 868.66M | 231.98M | 36.43% |
| Dec 31, 2022 | 636.69M | 279.15M | 78.08% |
| Dec 31, 2021 | 357.54M | 117.30M | 48.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals | 19.01B |
| PharmaEssentia | 15.63B |
| Nang Kuang Pharmaceutical | 2.16B |
| Onyx Healthcare | 1.31B |
| Maxigen Biotech | 811.56M |
| Genovate Biotechnology | 492.41M |
| Sagittarius Life Science | 346.08M |
| Caliway Biopharmaceuticals | 38.04M |